Advertisement

Annals of Hematology

, Volume 98, Issue 2, pp 501–510 | Cite as

Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors

  • Sang-A Kim
  • Jayoun Lee
  • Joon Ho Moon
  • Hyewon Lee
  • Junho Jang
  • June-Won Cheong
  • Jeonghwan Youk
  • Yeonjoo Choi
  • Minjoo Kang
  • Minkyung Shin
  • Youngil KohEmail author
  • Sangjin ShinEmail author
Original Article
  • 123 Downloads

Abstract

The advent of various alternative donors in allogeneic hematopoietic stem cell transplantation (HSCT) raises the question of using international donors, especially in ethnically homogenous populations. We analyzed the clinical outcome and medical expense of human leukocyte antigen (HLA)-matched HSCT using domestic and international donors. We analyzed the patients who received allogeneic HSCT at five medical centers in Korea in the last 10 years. Using propensity-score matching, we compared overall survival (OS), relapse-free survival (RFS), and transplantation-related complications. Medical expense was analyzed based on National Health Insurance Service (NHIS) data. A total of 269 patients were analyzed after 3:1 (domestic/international) matching. There was no difference in OS (p = 0.395) and RFS (p = 0.604) between the domestic and international donor groups (5-year OS rate 42.9 and 37.8%, 5-year RFS rate 37.6 and 33.5% for domestic and international groups, respectively). No difference in chronic graft-versus-host disease (GVHD) incidence was observed (34.2% in domestic and 35.9% in international group, p = 0.804). Early infection was more frequent in the domestic group (55.0 vs. 35.8%, p = 0.007), whereas infection after 30 days was more frequent in the international group (28.7 vs. 49.3%, p = 0.001). Mean medical expense was far higher in the international group, by US $51,944 in the entire follow-up period (p < 0.001). We would expect similar outcomes for international and domestic donors in terms of survival and treatment-related complications with HLA-matched HSCT in other ethnically homogenous populations. These findings should be considered together with the high cost of using international donors in the era of various alternative donors.

Keywords

Allogeneic stem cell transplantation HLA International donor Alternative donor 

Notes

Acknowledgements

This study was supported by the National Evidence-based Healthcare Collaborating Agency (NC15-005, NC16-001).

Compliance with ethical standards

Conflict of interest

Sang-A Kim declares that there is no conflict of interest regarding the work described in this article.

Jayoun Lee declares that there is no conflict of interest regarding the work described in this article.

Junho Moon declares that there is no conflict of interest regarding the work described in this article.

Hyewon Lee declares that there is no conflict of interest regarding the work described in this article.

Junho Jang declares that there is no conflict of interest regarding the work described in this article.

June-Won Cheong declares that there is no conflict of interest regarding the work described in this article.

Jeonghwan Youk declares that there is no conflict of interest regarding the work described in this article.

Yeonjoo Choi declares that there is no conflict of interest regarding the work described in this article.

Minkyung shin declares that there is no conflict of interest regarding the work described in this article.

Youngil Koh declares that there is no conflict of interest regarding the work described in this article.

Sangjin Shin declares that there is no conflict of interest regarding the work described in this article.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was waived due to the retrospective nature of this study.

References

  1. 1.
    Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354(17):1813–1826.  https://doi.org/10.1056/NEJMra052638 CrossRefGoogle Scholar
  2. 2.
    Norkin M, Wingard JR (2017) Recent advances in hematopoietic stem cell transplantation. F1000Res 6:870.  https://doi.org/10.12688/f1000research.11233.1 CrossRefGoogle Scholar
  3. 3.
    Furst D, Muller C, Vucinic V, Bunjes D, Herr W, Gramatzki M, Schwerdtfeger R, Arnold R, Einsele H, Wulf G, Pfreundschuh M, Glass B, Schrezenmeier H, Schwarz K, Mytilineos J (2013) High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood 122(18):3220–3229.  https://doi.org/10.1182/blood-2013-02-482547 CrossRefGoogle Scholar
  4. 4.
    Oh HB, Kim SI, Park MH, Akaza T, Juji T (1999) Probability of finding HLA-matched unrelated marrow donors for Koreans and Japanese from the Korean and Japan Marrow Donor Programs. Tissue Antigens 53(4 Pt 1):347–349CrossRefGoogle Scholar
  5. 5.
    Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D, Maiers M (2014) HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371(4):339–348.  https://doi.org/10.1056/NEJMsa1311707 CrossRefGoogle Scholar
  6. 6.
    Pappas DJ, Tomich A, Garnier F, Marry E, Gourraud PA (2015) Comparison of high-resolution human leukocyte antigen haplotype frequencies in different ethnic groups: consequences of sampling fluctuation and haplotype frequency distribution tail truncation. Hum Immunol 76(5):374–380.  https://doi.org/10.1016/j.humimm.2015.01.029 CrossRefGoogle Scholar
  7. 7.
    Rivera-Franco MM, Leon-Rodriguez E, Castro-Saldana HL (2017) Costs of hematopoietic stem cell transplantation in a developing country. Int J Hematol 106:573–580.  https://doi.org/10.1007/s12185-017-2278-1 CrossRefGoogle Scholar
  8. 8.
    van Agthoven M, Groot MT, Verdonck LF, Lowenberg B, Schattenberg AV, Oudshoorn M, Hagenbeek A, Cornelissen JJ, Uyl-de Groot CA, Willemze R (2002) Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 30(4):243–251.  https://doi.org/10.1038/sj.bmt.1703641 CrossRefGoogle Scholar
  9. 9.
    Blommestein HM, Verelst SG, Huijgens PC, Blijlevens NM, Cornelissen JJ, Uyl-de Groot CA (2012) Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann Hematol 91(12):1945–1952.  https://doi.org/10.1007/s00277-012-1530-2 CrossRefGoogle Scholar
  10. 10.
    Ballen KK, Gluckman E, Broxmeyer HE (2013) Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122(4):491–498.  https://doi.org/10.1182/blood-2013-02-453175 CrossRefGoogle Scholar
  11. 11.
    Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641–650.  https://doi.org/10.1016/j.bbmt.2008.03.005 CrossRefGoogle Scholar
  12. 12.
    Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kroger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden JA, Styczynski J, Mohty M (2017) Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 52:811–817.  https://doi.org/10.1038/bmt.2017.34 CrossRefGoogle Scholar
  13. 13.
    Reisner Y, Hagin D, Martelli MF (2011) Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 118(23):6006–6017.  https://doi.org/10.1182/blood-2011-07-338822 CrossRefGoogle Scholar
  14. 14.
    Shin MK, Shin S, Lee JY, Koh Y (2017) Physicians’ preferences and perceptions regarding donor selection in allogeneic stem cell transplantation in Korea when a matched domestic donor is not available. Blood research 52(1):31–36.  https://doi.org/10.5045/br.2017.52.1.31 CrossRefGoogle Scholar
  15. 15.
    Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ (1983) A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 302(5904):159–161CrossRefGoogle Scholar
  16. 16.
    Khera N, Chang YH, Slack J, Fauble V, Leis JF, Noel P, Sproat L, Palmer J, Adams R, Fitch T, Northfelt D, Guy M, Tilburt J, Mikhael J (2015) Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation. Leuk Lymphoma 56(4):987–992.  https://doi.org/10.3109/10428194.2014.941834 CrossRefGoogle Scholar
  17. 17.
    Madbouly A, Wang T, Haagenson M, Paunic V, Vierra-Green C, Fleischhauer K, Hsu KC, Verneris MR, Majhail NS, Lee SJ, Spellman SR, Maiers M (2017) Investigating the association of genetic admixture and donor/recipient genetic disparity with transplant outcomes. Biol Blood Marrow Transplant 23(6):1029–1037.  https://doi.org/10.1016/j.bbmt.2017.02.019 CrossRefGoogle Scholar
  18. 18.
    Park H, Lee YJ, Shin SJ, Lee J, Park S, Kim I, Moon JH, Lee H, Jang JH, Yoon SS, Koh Y (2018) Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. Leuk Res 69:31–38.  https://doi.org/10.1016/j.leukres.2018.04.002 CrossRefGoogle Scholar
  19. 19.
    Jee Sook H, Sun Ju L, Wang Kyun P, Yun Woong K, Hyun OKK, Samuel YL (1990) A survey on the cytomegalovirus antibodies in blood donors and the diseased. Korean J Blood Transfus 1(1):21–33Google Scholar
  20. 20.
    Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335–347.  https://doi.org/10.1056/NEJMoa061098 CrossRefGoogle Scholar
  21. 21.
    Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, Kodera Y (2016) Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 22(1):23–26.  https://doi.org/10.1016/j.bbmt.2015.11.001 CrossRefGoogle Scholar
  22. 22.
    OECD Health expenditure indicatorsGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Sang-A Kim
    • 1
  • Jayoun Lee
    • 2
  • Joon Ho Moon
    • 3
  • Hyewon Lee
    • 4
  • Junho Jang
    • 5
  • June-Won Cheong
    • 6
  • Jeonghwan Youk
    • 7
  • Yeonjoo Choi
    • 1
  • Minjoo Kang
    • 2
  • Minkyung Shin
    • 2
  • Youngil Koh
    • 1
    • 2
    Email author
  • Sangjin Shin
    • 2
    Email author
  1. 1.Department of Internal MedicineSeoul National University HospitalSeoulSouth Korea
  2. 2.National Evidence-based healthcare Collaborating AgencySeoulSouth Korea
  3. 3.Department of Internal MedicineKyungpook National University HospitalDaeguSouth Korea
  4. 4.Department of Internal MedicineNational Cancer CenterGoyangSouth Korea
  5. 5.Department of Internal MedicineSungkyunkwan University School of MedicineSeoulSouth Korea
  6. 6.Department of Internal MedicineYonsei University College of MedicineSeoulSouth Korea
  7. 7.Korea Advanced Institute of Science and TechnologyDaejeonSouth Korea

Personalised recommendations